Hormonal
The combination of oral estrogen use with prothrombotic mutations (Factor V Leiden or Prothrombin G20210A) or obesity significantly enhances the risk of venous thromboembolism.
If you have a known blood clotting mutation (like Factor V Leiden) or are overweight/obese, taking oral estrogen significantly increases your risk of blood clots (up to 8 times higher for mutations). However, using transdermal estrogen (patches/gels) does not appear to add extra risk for these high-risk groups, making it a safer choice to discuss with your doctor.
The combination of oral oestrogen and thrombogenic mutations or obesity further enhanced the risk of venous thromboembolism... odds ratio 8.0, 5.4 to 11.9... combination of current oral oestrogen use and an increased body mass index resulted in a further increase in the risk of venous thromboembolism (pooled odds ratio 5.4, 2.9 to 10.0)
Why this rating
Meta-analysis of multiple case-control studies and RCTs (WHI).
Source
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis
Marianne Canonico et al. · BMJ · 2008
DOI 10.1136/bmj.39555.441944.be
More from this paper
- Current use of oral estrogen increases the risk of venous thromboembolism in postmenopausal women, with the highest risk occurring during the first year of treatment.Strong
- Transdermal estrogen does not significantly increase the risk of venous thromboembolism in postmenopausal women, unlike oral estrogen.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →